Q&A: Meredith McKean on melanoma analysis at Sarah Cannon | Well being Care

Health Care Research







Meredith McKean

Meredith McKean




Utilizing the identical expertise as some COVID-19 vaccines, researchers at regionally based mostly Sarah Cannon Analysis Institute could have discovered a technique to cut back the chance of recurrence for melanoma sufferers. 

The section II research discovered that including a customized mRNA vaccine to current immunotherapy therapies resulted in a 44 % lower within the danger of recurrence for melanoma sufferers the place the most cancers was already eliminated or handled. All the sufferers have been on Keytruda, a FDA-approved immunotherapy drug, which already decreases danger of recurrence by 40 to 50 %, stated Meredith McKean, director of melanoma and pores and skin most cancers analysis for Sarah Cannon Analysis Institute, the analysis arm of HCA Healthcare’s most cancers institute, Sarah Cannon Most cancers Middle.